Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Parallel, Stratified, Multi-center, 12-Week Study Comparing the Safety & Efficacy of Fluticasone and Formoterol Combination (FlutiForm(tm)100/10 µg Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI)With the Administration of Placebo or Fluticasone (100 µg Twice Daily) and Formoterol (10 µg Twice Daily) Alone in Adolescent and Adult Patients With Mild to Moderate Asthma
Brief Summary: The purpose of this study is to compare the efficacy and safety of the fixed combination asthma drug FlutiForm HFA MDI with its two components administered alone, fluticasone propionate and formoterol fumarate, and with placebo in adult and adolescent patients with mild to moderate asthma.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone propionate/formoterol fumarate 100/10 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate 100 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol fumarate 10 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone propionate/formoterol fumarate 100/10; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fluticasone propionate 100; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Formoterol fumarate 10; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
B: Arm Label: FF 100mcg once daily; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate, Drug: albuterol/salbutamol | Arm Label: FF 200mcg once daily; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate, Drug: albuterol/salbutamol | Intervention Type: DRUG; Name: fluticasone furoate; Assigned to Arm(s): FF 100mcg once daily, FF 200mcg once daily | Intervention Type: DRUG; Name: albuterol/salbutamol; Assigned to Arm(s): FF 100mcg once daily, FF 200mcg once daily
C: Arm Label: Fluticasone furoate/Vilanterol (GW642444); Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate/Vilanterol Inhalation Powder, Drug: Placebo (2) | Arm Label: Fluticasone propionate/salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/salmeterol Inhalation Powder, Drug: Placebo (1) | Intervention Type: DRUG; Name: Fluticasone furoate/Vilanterol Inhalation Powder; Assigned to Arm(s): Fluticasone furoate/Vilanterol (GW642444) | Intervention Type: DRUG; Name: Fluticasone propionate/salmeterol Inhalation Powder; Assigned to Arm(s): Fluticasone propionate/salmeterol | Intervention Type: DRUG; Name: Placebo (1); Assigned to Arm(s): Fluticasone propionate/salmeterol | Intervention Type: DRUG; Name: Placebo (2); Assigned to Arm(s): Fluticasone furoate/Vilanterol (GW642444)
D: Arm Label: Fluticasone Furoate OD and Placebo BID; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate, Drug: Placebo | Arm Label: Fluticasone Propionate BID and Placebo OD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate, Drug: Placebo | Arm Label: Placebo only BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone propionate; Assigned to Arm(s): Fluticasone Propionate BID and Placebo OD | Intervention Type: DRUG; Name: Fluticasone furoate; Assigned to Arm(s): Fluticasone Furoate OD and Placebo BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Fluticasone Furoate OD and Placebo BID, Fluticasone Propionate BID and Placebo OD, Placebo only BID

Answer: A